Phil Nadeau
Stock Analyst at TD Cowen
(2.82)
# 1,670
Out of 5,122 analysts
24
Total ratings
52.17%
Success rate
34.38%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $175 → $200 | $139.67 | +43.19% | 1 | Dec 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $50 → $45 | $23.13 | +94.55% | 1 | Oct 31, 2025 | |
| KURA Kura Oncology | Reiterates: Buy | n/a | $8.29 | - | 1 | Nov 21, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $108.29 | -39.98% | 2 | Nov 6, 2024 | |
| BIIB Biogen | Maintains: Buy | $300 → $275 | $180.71 | +52.18% | 6 | Oct 31, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $57.97 | +107.02% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $471.16 | +6.12% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $28.02 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $15.43 | - | 1 | Jul 7, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $5.94 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.54 | - | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.05 | - | 1 | Jul 16, 2018 |
Neurocrine Biosciences
Dec 5, 2025
Maintains: Buy
Price Target: $175 → $200
Current: $139.67
Upside: +43.19%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $50 → $45
Current: $23.13
Upside: +94.55%
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $8.29
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $108.29
Upside: -39.98%
Biogen
Oct 31, 2024
Maintains: Buy
Price Target: $300 → $275
Current: $180.71
Upside: +52.18%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $57.97
Upside: +107.02%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $471.16
Upside: +6.12%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $28.02
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $15.43
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.94
Upside: -
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $6.54
Upside: -
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $6.05
Upside: -